Balancing Complement Inhibition and Infection Risk in C3G Treatment

Video content above is prompted by the following:

Summary for Physicians on Use of Complement Inhibitors in High-Risk Patients:

Identifying High-Risk Patients:

• Patients with nephrotic syndrome who experience significant protein loss, leading to very low IgG levels, are at an increased risk for infections. These patients may not be ideal candidates for complement inhibitors due to concerns about their ability to fight bacterial infections, particularly encapsulated organisms.

Risk of Infections and Safety Concerns:

• Early trial data, particularly from studies like VALIANT and APEX, suggest that while complement inhibitors are used in posttransplant patients on immunosuppressive therapy, they did not significantly increase the risk of infections, especially when vaccinated and managed with prophylactic antibiotics.
• Vaccination and prophylactic antibiotics (e.g., penicillin or macrolides) are essential to reduce infection risks when using complement inhibitors. It’s important to assess local infection resistance patterns (e.g., penicillin resistance rates) before initiating therapy.

Exclusion Criteria in Clinical Trials:

• Clinical trials, such as the APEX trial, excluded patients with a history of recurrent invasive infections caused by encapsulated organisms. However, in clinical practice, the timing of infections, vaccination status, and use of prophylactic antibiotics are important factors to consider.
• A patient who has had a meningococcal infection but was not vaccinated may still be a candidate for complement inhibitor therapy if vaccinations are administered and prophylactic antibiotics are used.

Pathways to Safe Use:

• In real-world settings, physicians may proceed with complement inhibitors in high-risk patients, provided that adequate precautions are taken, including vaccination, use of prophylactic antibiotics, and consultation with infectious disease specialists when necessary. This approach has been successful in managing patients safely over extended periods.

Patient and Parental Concerns:

• It’s crucial to address concerns from parents or caregivers, particularly in pediatric populations. Parents need reassurance regarding the safety of long-term use of complement inhibitors, especially in the context of infection risks.